Skip to Main Content

Author Details

William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
1987
349
124
PMIDPaper TitleJournal TitlePublished Year
36459568Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.Cancer Res2023
37922313Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis.Cell Rep2023
37612728Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.Genome Biol2023
37030295USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.Cell Rep Med2023
37024492Mapping the landscape of genetic dependencies in chordoma.Nat Commun2023
36576405A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas.Cancer Discov2023
36574667Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling.Proc Natl Acad Sci U S A2023
37394429An Atlas of Variant Effects to understand the genome at nucleotide resolution.Genome Biol2023
36747859Compressed phenotypic screens for complex multicellular models and high-content assays.bioRxiv2023
36548402Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.Cancer Res2023
37237081Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.Nat Cancer2023
36989360Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation.Sci Adv2023
36459568Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.Cancer Res2023
37612728Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.Genome Biol2023
37922313Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis.Cell Rep2023
37394429An Atlas of Variant Effects to understand the genome at nucleotide resolution.Genome Biol2023
37024492Mapping the landscape of genetic dependencies in chordoma.Nat Commun2023
36989360Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation.Sci Adv2023
37237081Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.Nat Cancer2023
37030295USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.Cell Rep Med2023
36548402Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.Cancer Res2023
36747859Compressed phenotypic screens for complex multicellular models and high-content assays.bioRxiv2023
36576405A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas.Cancer Discov2023
36574667Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling.Proc Natl Acad Sci U S A2023
35058622Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
36040810VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.JCI Insight2022
35831509Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.Nature2022
35437317Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.Nat Cancer2022
35365656Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.Nat Commun2022
35550030CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.Elife2022
36258042Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35058622Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35085500Sparse dictionary learning recovers pleiotropy from human cell fitness screens.Cell Syst2022
35550030CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.Elife2022
35437317Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.Nat Cancer2022
35831509Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.Nature2022
35365656Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.Nat Commun2022
36040810VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.JCI Insight2022
36258042Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35085500Sparse dictionary learning recovers pleiotropy from human cell fitness screens.Cell Syst2022
33406420Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.Cell Rep2021
33753930A first-generation pediatric cancer dependency map.Nat Genet2021
33534641Predicting cell health phenotypes using image-based morphology profiling.Mol Biol Cell2021
33526449A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective.Mol Cell Biol2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
34261517Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.Genome Med2021
34260938Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.Cell Rep2021
33926920<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.Cancer Discov2021
33500573Cancer research needs a better map.Nature2021
34320363SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.Cell Rep2021
  • 1 - 50 of 698

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 38
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 7
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 3
Kevin R Brown
College Street, University of Toronto
Career Start Year 2000
Number of shared co-authors 10
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 2
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 7
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 2
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 11
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 18
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 33
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 12
Julien Sage
Department of Pediatrics Stanford University Stanford California USA.
Career Start Year 1993
Number of shared co-authors 9
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 1
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 47
James DeGregori
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 4
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 13
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 7
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 8
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 27
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 10
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 13
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 13
Ralf Kittler
McDermott Center for Human Growth and Development.
Career Start Year 1984
Number of shared co-authors 13
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 21
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 8
Norman E Sharpless
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 20

Collaborators

David E Root
Broad Institute of Harvard and MIT
Co-authored papers 68
Francisca Vazquez
Broad Institute of MIT and Harvard
Co-authored papers 57
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 54
Aviad Tsherniak
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard
Co-authored papers 45
Matthew Meyerson
Broad Institute
Co-authored papers 41
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 38
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 36
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 27
Anna C Schinzel
Co-authored papers 26
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 22
Rameen Beroukhim
Co-authored papers 22
Pablo Tamayo
University of California San Diego
Co-authored papers 21
John G Doench
Co-authored papers 18
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 17
Keith L Ligon
Co-authored papers 17
Glenn S Cowley
Broad Institute of Harvard and MIT
Co-authored papers 17
Laura E MacConaill
Co-authored papers 17
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 16
Jill P Mesirov
University of California San Diego
Co-authored papers 15
Paul Van Hummelen
Co-authored papers 15
Charles W M Roberts
Co-authored papers 14
Federica Piccioni
Co-authored papers 14
Ian F Dunn
Co-authored papers 13
Joseph Rosenbluh
Co-authored papers 13
Eric S Lander
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 12
Lynda Chin
Co-authored papers 12
David M Sabatini
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Co-authored papers 11
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers 11
James E Bradner
Co-authored papers 11
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 10
Release 1.2